Your browser doesn't support javascript.
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Corominas, Hèctor; Castellví, Ivan; Diaz-Torné, César; Matas, Laia; de la Rosa, David; Mangues, Maria Antònia; Moya, Patricia; Pomar, Virginia; Benito, Natividad; Moga, Ester; Sosa, Nerea Hernandez-de; Casademont, Jordi; Domingo, Pere.
  • Corominas H; Servei de Reumatologia.
  • Castellví I; Servei de Reumatologia.
  • Diaz-Torné C; Servei de Reumatologia.
  • Matas L; Servei de Medicina Interna.
  • de la Rosa D; Servei de Pneumologia.
  • Mangues MA; Servei de Farmàcia Hospitalària.
  • Moya P; Servei de Reumatologia.
  • Pomar V; Unitat de Malalties Infeccioses.
  • Benito N; Unitat de Malalties Infeccioses.
  • Moga E; Servei Immunologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
  • Sosa NH; Servei de Medicina Interna.
  • Casademont J; Servei de Medicina Interna.
  • Domingo P; Unitat de Malalties Infeccioses.
Medicine (Baltimore) ; 100(19): e25923, 2021 May 14.
Article in English | MEDLINE | ID: covidwho-1455404
ABSTRACT
ABSTRACT Blocking IL-6 pathways with sarilumab, a fully human anti-IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used "off-label" sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-6 / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / COVID-19 Drug Treatment Type of study: Observational study Limits: Aged / Humans / Male / Middle aged Language: English Journal: Medicine (Baltimore) Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-6 / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / COVID-19 Drug Treatment Type of study: Observational study Limits: Aged / Humans / Male / Middle aged Language: English Journal: Medicine (Baltimore) Year: 2021 Document Type: Article